Abstract
the presence of Anti-factor Xa (AFXa) for dose adjustment. However, currently there are no guidelines for LMWH monitoring in patients on thromboprophylactic, doses, despite certain patient populations may be at risk of suboptimal dosing. This review found that while the AFXa ranges for therapeutic levels of LMWHs are relatively well defined in the literature, prophylactic ranges are much less clear, thus making it difficult to interpret current research data. From the studies published to date, we concluded that a reasonable AFXa target range for LMWH deep venous thromboses prophylaxis might be 0.2-0.5 IU/mL.
| Original language | English |
|---|---|
| Article number | 5844 |
| Pages (from-to) | 80-83 |
| Number of pages | 4 |
| Journal | Hematology Reports |
| Volume | 7 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 23 Nov 2015 |
Cite this
}
The anti-factor Xa range for low molecular weight heparin thromboprophylaxis. / Ward, Salena May; Wei, Matthew Yuankun.
In: Hematology Reports, Vol. 7, No. 4, 5844, 23.11.2015, p. 80-83.Research output: Contribution to journal › Article › Other › peer-review
TY - JOUR
T1 - The anti-factor Xa range for low molecular weight heparin thromboprophylaxis
AU - Ward, Salena May
AU - Wei, Matthew Yuankun
PY - 2015/11/23
Y1 - 2015/11/23
N2 - Low molecular weight heparins (LMWHs) are now the mainstay option in the prevention and treatment of venous thromboembolism. In some patients receiving therapeutic doses of LMWH, activity can be measured by quantifyingthe presence of Anti-factor Xa (AFXa) for dose adjustment. However, currently there are no guidelines for LMWH monitoring in patients on thromboprophylactic, doses, despite certain patient populations may be at risk of suboptimal dosing. This review found that while the AFXa ranges for therapeutic levels of LMWHs are relatively well defined in the literature, prophylactic ranges are much less clear, thus making it difficult to interpret current research data. From the studies published to date, we concluded that a reasonable AFXa target range for LMWH deep venous thromboses prophylaxis might be 0.2-0.5 IU/mL.
AB - Low molecular weight heparins (LMWHs) are now the mainstay option in the prevention and treatment of venous thromboembolism. In some patients receiving therapeutic doses of LMWH, activity can be measured by quantifyingthe presence of Anti-factor Xa (AFXa) for dose adjustment. However, currently there are no guidelines for LMWH monitoring in patients on thromboprophylactic, doses, despite certain patient populations may be at risk of suboptimal dosing. This review found that while the AFXa ranges for therapeutic levels of LMWHs are relatively well defined in the literature, prophylactic ranges are much less clear, thus making it difficult to interpret current research data. From the studies published to date, we concluded that a reasonable AFXa target range for LMWH deep venous thromboses prophylaxis might be 0.2-0.5 IU/mL.
UR - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691677/pdf/hr-2015-4-5844.pdf
U2 - 10.4081/hr.2015.5844
DO - 10.4081/hr.2015.5844
M3 - Article
VL - 7
SP - 80
EP - 83
JO - Hematology Reports
JF - Hematology Reports
SN - 2038-8322
IS - 4
M1 - 5844
ER -